| Chickenpox
Gamastan vs Varizig
Side-by-side clinical, coverage, and cost comparison for chickenpox.Deep comparison between: Gamastan vs Varizig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVarizig has a higher rate of injection site reactions vs Gamastan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Varizig but not Gamastan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gamastan
Varizig
At A Glance
IM injection
Passive immunizing agent
IM injection
Single dose
Varicella-zoster immune globulin
Indications
- Hepatitis A
- Measles
- Chickenpox
- Rubella
- Chickenpox
Dosing
Hepatitis A 0.1 mL/kg within 2 weeks of exposure or for travel stays up to 1 month; 0.2 mL/kg for stays up to 2 months or longer, repeated every 2 months; administer IM.
Measles 0.25 mL/kg IM within 6 days of exposure in susceptible persons; 0.5 mL/kg IM immediately (maximum 15 mL) for immunocompromised children.
Chickenpox 0.6 mL/kg to 1.2 mL/kg IM promptly when Varicella-Zoster Immune Globulin (Human) is unavailable.
Rubella 0.55 mL/kg IM administered only to exposed pregnant women who will not consider therapeutic abortion.
Chickenpox Single weight-based IM dose: 62.5 IU (<=2 kg) to 625 IU (>=40.1 kg); divide into 2 or more injection sites (max 3 mL per site); administer as soon as possible after VZV exposure; consider a second full dose for high-risk patients re-exposed more than 3 weeks after initial administration.
Contraindications
- Anaphylactic or severe systemic hypersensitivity reactions to Immune Globulin (Human)
- IgA deficiency with antibodies against IgA and a history of hypersensitivity
- Anaphylactic or severe systemic hypersensitivity reaction to human immune globulin preparations
- IgA deficiency with antibodies against IgA and a history of hypersensitivity (risk of anaphylactoid reaction)
Adverse Reactions
Most common Fatigue
Postmarketing Anaphylactic reaction, hypersensitivity (rash, flushing, dyspnea), headache, nausea, injection site pain, injection site inflammation, pyrexia
Most common (>=1%) Injection site pain, headache, rash (including pruritus, rash erythematous, rash vesicular, urticaria), fatigue, chills, nausea
Serious Pyrexia, nausea, vomiting
Pharmacology
Polyclonal passive immunizing agent; antibodies in Gamastan neutralize viruses such as hepatitis A and measles to prevent or ameliorate disease.
VARIZIG is a human immune globulin G (IgG) preparation containing antibodies to varicella zoster virus (anti-VZV) that provides passive immunization for non-immune individuals exposed to VZV, reducing the severity of varicella infections.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gamastan
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
Varizig
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Gamastan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Varizig
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gamastan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Varizig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Primary Immunodeficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Varizig.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GamastanView full Gamastan profile
VarizigView full Varizig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.